BR112018072719A2 - molécula de ácido nucleico isolada, composição, e, métodos de indução de uma resposta imune contra o filovírus e o ebolavirus, de tratamento de um indivíduo que foi diagnosticado com ebolavirus e de prevenção da infecção por ebolavirus - Google Patents

molécula de ácido nucleico isolada, composição, e, métodos de indução de uma resposta imune contra o filovírus e o ebolavirus, de tratamento de um indivíduo que foi diagnosticado com ebolavirus e de prevenção da infecção por ebolavirus

Info

Publication number
BR112018072719A2
BR112018072719A2 BR112018072719-9A BR112018072719A BR112018072719A2 BR 112018072719 A2 BR112018072719 A2 BR 112018072719A2 BR 112018072719 A BR112018072719 A BR 112018072719A BR 112018072719 A2 BR112018072719 A2 BR 112018072719A2
Authority
BR
Brazil
Prior art keywords
ebolavirus
methods
nucleic acid
inducing
treating
Prior art date
Application number
BR112018072719-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Patel Ami
Yan Jian
Weiner David
Original Assignee
The Trustees Of The University Of Pennsylvania
The Wistar Institute Of Anatomy And Biology
Inovio Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania, The Wistar Institute Of Anatomy And Biology, Inovio Pharmaceuticals, Inc. filed Critical The Trustees Of The University Of Pennsylvania
Publication of BR112018072719A2 publication Critical patent/BR112018072719A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112018072719-9A 2016-05-05 2017-05-05 molécula de ácido nucleico isolada, composição, e, métodos de indução de uma resposta imune contra o filovírus e o ebolavirus, de tratamento de um indivíduo que foi diagnosticado com ebolavirus e de prevenção da infecção por ebolavirus BR112018072719A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662332372P 2016-05-05 2016-05-05
US62/332,372 2016-05-05
US201662402519P 2016-09-30 2016-09-30
US62/402,519 2016-09-30
US201762483979P 2017-04-11 2017-04-11
US62/483,979 2017-04-11
PCT/US2017/031215 WO2017192947A1 (en) 2016-05-05 2017-05-05 Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same

Publications (1)

Publication Number Publication Date
BR112018072719A2 true BR112018072719A2 (pt) 2019-02-19

Family

ID=60203604

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072719-9A BR112018072719A2 (pt) 2016-05-05 2017-05-05 molécula de ácido nucleico isolada, composição, e, métodos de indução de uma resposta imune contra o filovírus e o ebolavirus, de tratamento de um indivíduo que foi diagnosticado com ebolavirus e de prevenção da infecção por ebolavirus

Country Status (11)

Country Link
US (3) US11091518B2 (enExample)
EP (1) EP3452068A4 (enExample)
JP (3) JP7029756B2 (enExample)
KR (2) KR102678400B1 (enExample)
CN (2) CN117887735A (enExample)
AU (2) AU2017261306B2 (enExample)
BR (1) BR112018072719A2 (enExample)
CA (1) CA3023098A1 (enExample)
MX (2) MX2018013524A (enExample)
SG (2) SG10202011017RA (enExample)
WO (1) WO2017192947A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110655572A (zh) * 2019-10-11 2020-01-07 中国科学院广州生物医药与健康研究院 一种抗丝状病毒gp蛋白的单克隆抗体及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117887735A (zh) * 2016-05-05 2024-04-16 宾夕法尼亚大学理事会 丝状病毒共有抗原、核酸构建体和由其制成的疫苗及其使用方法
KR20190114963A (ko) * 2016-12-02 2019-10-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 에볼라 바이러스에 대한 사용을 위한 dna 항체 작제물
WO2024233996A2 (en) * 2023-05-11 2024-11-14 The Wistar Institute Of Anatomy And Biology Vaccines against african swine fever virus, and methods of using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
KR102877352B1 (ko) * 2012-04-12 2025-10-29 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법
CN114045295A (zh) * 2013-03-15 2022-02-15 宾夕法尼亚大学理事会 口蹄疫病毒(fmdv)共有蛋白、其编码序列以及由其制造的疫苗
CN107454848B (zh) * 2014-09-03 2021-06-22 巴法里安诺迪克有限公司 用于诱导针对丝状病毒感染的保护性免疫的方法和组合物
US10166288B2 (en) 2014-10-01 2019-01-01 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-21 as an adjuvant
CN117887735A (zh) * 2016-05-05 2024-04-16 宾夕法尼亚大学理事会 丝状病毒共有抗原、核酸构建体和由其制成的疫苗及其使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110655572A (zh) * 2019-10-11 2020-01-07 中国科学院广州生物医药与健康研究院 一种抗丝状病毒gp蛋白的单克隆抗体及其应用

Also Published As

Publication number Publication date
JP2025017370A (ja) 2025-02-05
AU2024203524A1 (en) 2024-06-20
WO2017192947A1 (en) 2017-11-09
JP2019516400A (ja) 2019-06-20
US11091518B2 (en) 2021-08-17
KR20190037200A (ko) 2019-04-05
KR20240099514A (ko) 2024-06-28
US20250257101A1 (en) 2025-08-14
EP3452068A4 (en) 2020-01-22
AU2017261306A1 (en) 2018-12-20
CA3023098A1 (en) 2017-11-09
JP7584770B2 (ja) 2024-11-18
CN110072536B (zh) 2024-02-02
CN117887735A (zh) 2024-04-16
SG11201809780WA (en) 2018-12-28
JP7029756B2 (ja) 2022-03-04
JP2022078067A (ja) 2022-05-24
AU2017261306B2 (en) 2024-02-29
SG10202011017RA (en) 2020-12-30
US20210388033A1 (en) 2021-12-16
EP3452068A1 (en) 2019-03-13
KR102678400B1 (ko) 2024-06-26
US20190153040A1 (en) 2019-05-23
MX2023003934A (es) 2023-04-26
MX2018013524A (es) 2019-06-10
CN110072536A (zh) 2019-07-30
US12240872B2 (en) 2025-03-04

Similar Documents

Publication Publication Date Title
IN2014DN09351A (enExample)
BR112022014808A2 (pt) Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
BR112018072719A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos de indução de uma resposta imune contra o filovírus e o ebolavirus, de tratamento de um indivíduo que foi diagnosticado com ebolavirus e de prevenção da infecção por ebolavirus
BR112018011975A2 (pt) composições úteis no tratamento de atrofia muscular espinhal
BR112016028816A2 (pt) combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit.
BRPI0906710B8 (pt) peptídeo derivado de pres modificado hidrofóbico de vírus da hepatite b (hbv) , peptídeo e composição farmacêutica
CL2018002826A1 (es) Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
BR112017014219A2 (pt) vacinas à base de nanopartículas multivalentes
BR112015021414A2 (pt) vírus da doença newcastle e seus usos
BR112017016417A2 (pt) moléculas de ligação dirigidas contra hemaglutinina da gripe e seus usos
MX363667B (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
EA201890355A1 (ru) Новые способы индукции иммунного ответа
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
BR112015002131A8 (pt) Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
BR112016029713A2 (pt) métodos para o tratamento de sobrepeso ou obesidade
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
WO2017066719A3 (en) Hu specific interfering agents
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
CY1124667T1 (el) Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα
BR112012031211A2 (pt) métodos e vacina para reduzir a infecção causada pelo campylobacter
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
BR112022022859A2 (pt) Vacinas contra sars-cov-2
BR112017018703A2 (pt) peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]